((1H-benzo[d]imidazol-2-yl)methyl)triphenylphosphonium chloride | 60912-44-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ((1H-benzo[d]imidazol-2-yl)methyl)triphenylphosphonium chloride
• 英文别名: (benzimidazol-2-ylmethyl)triphenylphosphonium chloride；2-[(triphenylphosphonium chloride)methyl]benzimidazole；2-(triphenylphosphonium chloride) benzimidazole；(1H-benzoimidazol-2-ylmethyl)-triphenyl-phosphonium chloride；(1H-benzimidazol-2-ylmethyl)triphenylphosphonium chloride；2-benzimidazolylmethyltriphenylphosphonium chloride；1H-benzimidazol-2-ylmethyl(triphenyl)phosphanium;chloride
• CAS: 60912-44-9
• 化学式: C₂₆H₂₂N₂P*Cl
• 分子量: 428.901
• InChiKey: NMKHOIKAXWBFEU-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  2.06
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.04
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  ((1H-benzo[d]imidazol-2-yl)methyl)triphenylphosphonium chloride 在 sodium hydroxide 作用下， 以 甲醇 、 乙腈 为溶剂， 反应 18.0h， 生成 2-allyl-1,2-dihydro-1-thioxopyrimido[3,4-a]benzimidazole
  参考文献：
  名称：

  摘要：

  The reaction of readily accessible (benzin-tidazol-2-ylmethyl)triphenylphosphonium chloride with acyl isothiocyanates in the presence of triethylamine, as well as consecutive treatment of the above phosphonium salt first with N,N-dimethylformamide dimethyl acetal and then with phenyl or allyl isothiocyanate gives two types of phosphorus-containing derivatives of pyrimido[1,6-a]benzimidazole with the thione group in position 3 or I of the condensed system. The structure of one of compounds of the first type, 3-thioxo-1-p-tolyl-3,4-dihydropyrimido[1,6-a]benzimidazol-4-ylidenetriphenylphosphorane, was determined by single crystal X-ray diffraction.

  DOI：

  10.1023/a:1023328910321
• 作为产物：
  描述：

  邻苯二胺 在 盐酸 作用下， 以 甲苯 为溶剂， 生成 ((1H-benzo[d]imidazol-2-yl)methyl)triphenylphosphonium chloride
  参考文献：
  名称：

  从多潜性二苯乙烯到具有抗增殖特性的可溶性环氧水解酶抑制剂

  摘要：

  受自然界的启发：天然产物异丙基苯乙烯被鉴定为具有抗增殖特性的可溶性环氧化物水解酶的抑制剂。遵循天然产物的设计方法，合成了（E）-styryl-1 H-苯并[ d ]咪唑文库，并用重组酶和在几种癌细胞系上进行了评估。

  DOI：

  10.1002/cmdc.201300057

文献信息

• [EN] HETEROCYCLIC MGLU5 ANTAGONISTS<br/>[FR] ANTAGONISTES HÉTÉROCYCLIQUES DE MGLU5
  申请人：RECORDATI IRELAND LTD

  公开号：WO2011029633A1

  公开（公告）日：2011-03-17

  Compounds (I) (R1 is an optionally substituted C1-C13 heteromonocyclic, heterobicyclic or heterotri cyclic group containing from 1 to 5 heteroatoms selected from N, O and S; R2 is H, an optionally substituted monocyclic aromatic group, or a C1-C5 heteroaromatic group containing from 1 to 4 heteroatoms selected from N, O and S; R3 is an optionally substituted C1-C13 heteromonocyclic, heterobicyclic or heterotri cyclic group containing from 1 to 5 heteroatoms selected from N, O and S; an optionally substituted mono-, bi- or tricyclic C6-C14 aryl group, an optionally substituted C3-C6 cycloalkyl group, or an optionally substituted C3-C6 cycloalkenyl group; each R4, independently for each position capable of substitution, is H or C1-C6 alkyl; R5 is H, halogen or C1-C6 alkyl; m is 0, 1 or 2; n is 0, 1 or 2; p is 0, 1, 2, 3, 4, 5, or 6; and --- is an optional double bond) and their enantiomers, diastereomers, N-oxides and pharmaceutically acceptable salts, and pharmaceutical compositions containing them, are useful for the treatment of neuromuscular dysfunction of the lower urinary tract and also for the treatment of gastrooesophageal reflux disease; anxiety disorder; abuse, substance dependence and substance withdrawal disorders; neuropathic pain disorder, migraine and fragile X syndrome disorders.

  化合物（I）（其中R1为任选取代的含1至5个选自N、O和S的杂原子的C1-C13杂单环、杂双环或杂三环基团；R2为H、任选取代的单环芳香基团或含1至4个选自N、O和S的杂原子的C1-C5杂芳香基团；R3为任选取代的含1至5个选自N、O和S的杂原子的C1-C13杂单环、杂双环或杂三环基团，任选取代的单环、双环或三环C6-C14芳基团，任选取代的C3-C6环烷基团，或任选取代的C3-C6环烯基团；每个R4独立地为每个可取代位置上的H或C1-C6烷基；R5为H、卤素或C1-C6烷基；m为0、1或2；n为0、1或2；p为0、1、2、3、4、5或6；---为任选的双键）及其对映体、非对映体、N-氧化物和药学上可接受的盐，以及含有它们的药物组合物，可用于治疗下尿路神经肌肉功能障碍以及胃食管反流病；焦虑障碍；滥用、物质依赖和物质戒断障碍；神经性疼痛障碍、偏头痛和脆性X综合征障碍。
• 2-Cyclohexyl quinazoline NMDA/NR2B antagonists
  申请人：——

  公开号：US20020032207A1

  公开（公告）日：2002-03-14

  4-substituted cyclohexanes substituted in the 1-position with quinazoline either directly or through a C 1 -C 4 alkyl, C 1 -C 4 alkenyl, C 1 -C 4 alkynyl, C 1 -C 4 alkoxy, amino, aminoC 1 -C 4 alkyl, hydroxyC 1 -C 4 alkyl, carbonyl, cycloC 3 -C 6 alkyl or aminocarbonyl chain are effective as NMDA NR2B antagonists useful for relieving pain.

  在1-位置用喹唑啉直接或通过C1-C4烷基、C1-C4烯基、C1-C4炔基、C1-C4烷氧基、氨基、氨基C1-C4烷基、羟基C1-C4烷基、羰基、环C3-C6烷基或氨甲酰链替代的4-取代环己烷是有效的NMDA NR2B拮抗剂，用于缓解疼痛。
• 2-cyclohexyl quinazoline NMDA/NR2B antagonists
  申请人：Merck & Co., Inc.

  公开号：US06380205B1

  公开（公告）日：2002-04-30

  4-substituted cyclohexanes substituted in the 1-position with quinazoline either directly or through a C1-C4alkyl, C1-C4alkenyl, C1-C4alkynyl, C1-C4alkoxy, amino, aminoC1-C4alkyl, hydroxyC1-C4alkyl, carbonyl, cycloC3-C6alkyl or aminocarbonyl chain are effective as NMDA NR2B antagonists useful for relieving pain.

  1-位置用喹唑啉直接或通过C1-C4烷基、C1-C4烯基、C1-C4炔基、C1-C4烷氧基、氨基、氨基C1-C4烷基、羟基C1-C4烷基、羰基、环C3-C6烷基或氨基羰基链取代的4-取代环己烷可作为NMDA NR2B拮抗剂，用于缓解疼痛。
• 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists
  申请人：——

  公开号：US20020055519A1

  公开（公告）日：2002-05-09

  4-substituted cyclohexanes substituted in the 1-position with imidazopyridine either directly or through a C 1 -C 4 alkyl, C 1 -C 4 alkenyl, C 1 -C 4 alkynyl, C 1 -C 4 alkoxy, amino, aminoC 1 -C 4 alkyl, hydroxyC 1 -C 4 alkyl, carbonyl, cycloC 3 -C 6 alkyl or aminocarbonyl chain are effective as NMDA NR2B antagonists useful for relieving pain.

  在1-位置用咪唑吡啶直接或通过C1-C4烷基、C1-C4烯基、C1-C4炔基、C1-C4烷氧基、氨基、氨基C1-C4烷基、羟基C1-C4烷基、羰基、环C3-C6烷基或氨基羰基链取代的4-取代环己烷对缓解疼痛有用，作为NMDA NR2B拮抗剂。
• 2-cyclohexyl benzimidazole NMDA/NR2B antagonists
  申请人：Merck & Co., Inc.

  公开号：US06291499B1

  公开（公告）日：2001-09-18

  Novel 4-substituted cyclohexanes substituted in the 1-position with 2-benzimidazoles, 2-imidazopyridines, or 4-imidazoles either directly or through a C1-C4alkyl, cycloalkyl, hydroxyalkyl, alkoxy or aminoalkyl chain are effective as NMDA NR2B antagonists useful for relieving pain.

  用2-苯并咪唑基、2-咪唑吡啶基或4-咪唑基在1-位置取代的新型4-取代环己烷，通过直接或通过C1-C4烷基、环烷基、羟基烷基、烷氧基或氨基烷链替代，可作为NMDA NR2B拮抗剂，用于缓解疼痛。